Read More Pharma Industry News PRX012 Alzheimer’s trial: Can Prothena rebound from birtamimab setback? After a major clinical failure, Prothena shifts focus to Alzheimer’s drug PRX012. Will this next trial restore investor confidence? byPallavi MadhirajuMay 25, 2025